Korean Botox

Korean Botox Manufacturers & Brands: The Complete Comparison Map

Korean Botox refers to botulinum toxin type A products manufactured in South Korea and used in neurotoxin aesthetic treatments. The rise of Korean Botox has been driven by manufacturing innovation in Korea, expanding international recognition, and a widening range of formulations that allow practitioners to select products based on workflow preferences, unit configurations, and regulatory status. Major manufacturers include Hugel, Medytox, Daewoong, and Huons, with brands differing primarily by formulation type, approval status, and manufacturer background.

For clinics evaluating Korean Botox brands, the manufacturer-to-brand relationship is usually the most efficient starting point. The major product landscape includes:

What Is Korean Botox?

The term “Korean Botox” generally refers to botulinum toxin type A products derived from Clostridium botulinum and manufactured in South Korea. These products work through the same fundamental mechanism as Western injectable neurotoxins, temporarily reducing the activity of targeted facial muscles, which makes them suitable for forehead lines, crow’s feet, glabellar lines, and other expression lines.

The growing popularity of Korean botulinum toxin products reflects sustained investment by South Korean manufacturers in GMP-compliant facilities, purification technology, and formulation development. That track record has established Korean neurotoxins as a recognized category within aesthetic medicine rather than a regional substitute.

Formulation Type: The First Major Comparison Axis

Among the Korean brands currently available, formulation type creates the most significant practical distinction.

INNOTOX® is the exception to the category: it is supplied as a liquid, ready-to-use formulation and does not require reconstitution before administration. This simplifies workflow, removes a preparation step, and eliminates the concentration variability that the dilution technique can introduce.

Every other major Korean brand (LETYBO™, BOTULAX®, NABOTA®, MEDITOXIN®, LIZTOX®, and Re N Tox®) is supplied as a lyophilized powder that must be reconstituted with sterile normal saline before use. For a busy practice, this single difference can weigh as heavily on product selection as price, regulatory status, or vial size.

Is Korean Botox Safe?

Safety should be evaluated on a brand-by-brand basis, using published clinical data, manufacturing standards, and regulatory oversight, rather than being generalized across the category.

Several Korean manufacturers have published evidence on the aesthetic use of their products. Studies of prabotulinumtoxinA (NABOTA®/Jeuveau®) have reported outcomes comparable to established botulinum toxin type A products in the treatment of glabellar lines. Published clinical research has likewise supported the safety and efficacy of letibotulinumtoxinA (LETYBO™) for moderate-to-severe glabellar lines.

The broader rise of Korean Botox has been backed by peer-reviewed evidence, international distribution, and continued investment in pharmaceutical manufacturing standards within South Korea. The practical takeaway for practitioners is to assess each product on its own data rather than assume that all Korean neurotoxins share identical clinical characteristics.

LETYBO™, INNOTOX® & NABOTA®: Brand Profiles for Key Comparison Queries

Among the leading Korean botulinum toxin products, LETYBO™, INNOTOX®, and NABOTA® are the brands practitioners most often compare, weighing formulation characteristics, manufacturer background, and regulatory recognition. All three are botulinum toxin type A products developed in South Korea, but they differ in ways that influence clinical workflow and procurement: LETYBO™ and NABOTA® are lyophilized, while INNOTOX® is a liquid, ready-to-use product that requires no reconstitution.

LETYBO™

LETYBO™ (letibotulinumtoxinA) is manufactured by Hugel in South Korea and supplied as a lyophilized formulation in 50-unit and 100-unit vials. For practitioners asking what LETYBO™ is or who makes LETYBO™, it is Hugel’s flagship neurotoxin, indicated for glabellar lines, and it received FDA approval in the United States in 2024 (current as of mid 2026). That approval makes it one of the most widely recognized Korean Botox brands internationally.

INNOTOX®

INNOTOX® is manufactured by Medytox and is the only liquid, ready-to-use Korean botulinum toxin type A, supplied in 50-unit and 100-unit presentations. Because it requires no reconstitution, it eliminates concentration variability introduced by the dilution technique — the primary clinical differentiator from other Korean brands. Regarding INNOTOX®’s safety, published clinical data support its tolerability and efficacy in the aesthetic indications studied, though safety review should remain brand- and indication-specific.

For practices weighing preparation efficiency, INNOTOX® injections offer a workflow advantage over lyophilized products.

BOTULAX®

BOTULAX® is a botulinum toxin type A product manufactured by Hugel in South Korea and supplied as a lyophilized formulation in 100-unit and 200-unit presentations, giving practices flexibility across treatment volumes and inventory needs. The 200-unit vial is particularly useful for clinics performing multiple neurotoxin procedures or treating several areas in a single session.

As part of Hugel’s portfolio, the same manufacturer behind FDA-approved LETYBO™, BOTULAX® draws on an established global aesthetics presence. Interest in the Korean Botox BOTULAX® continues to grow among practitioners seeking dosing flexibility paired with manufacturer recognition.

NABOTA®

NABOTA® is a botulinum toxin type A product manufactured by Daewoong in South Korea and supplied as a lyophilized formulation in 100-unit presentations. Its most notable distinction is regulatory recognition in the United States, where it is marketed as Jeuveau® (prabotulinumtoxinA-xvfs). NABOTA® has received FDA approval, though practitioners should verify current regulatory status before procurement (as of mid 2026).

Growing interest in this Korean Botox reflects the product’s international footprint, published clinical data, and established role in the global aesthetic medicine market.

MEDITOXIN®

MEDITOXIN® is manufactured by Medytox and available in 100-, 150-, and 200-unit formats, giving practitioners multiple options for different treatment volumes. Supplied as a lyophilized botulinum toxin type A formulation, it has been widely used across Asia and remains one of the more established Korean neurotoxin products.

Its broad unit range supports flexible inventory management and treatment planning, and as part of the same manufacturer portfolio as INNOTOX®, it draws on Medytox’s long-standing experience in botulinum toxin development.

Re N Tox®

Re N Tox® is a lyophilized botulinum toxin type A product available in selected international markets. Like other powdered neurotoxins, it requires reconstitution before administration and should be handled in accordance with the manufacturer’s storage and preparation guidelines.

Based on publicly available information, Re N Tox® is not currently FDA-approved in the United States (as of mid 2026). Because regulatory requirements vary by jurisdiction, clinics should confirm the product’s approval status and compliance requirements at the time of procurement.

Is Korean Botox FDA-approved? Brand-by-Brand Regulatory Status

When evaluating Korean botulinum toxin brands, regulatory approval is one of the most important factors to weigh. Although many products are used widely across global markets, only a limited number have received FDA approval.

FDA-Approved Korean Botox Brands

• LETYBO™: FDA-approved as letibotulinumtoxinA in 2024 (current as of mid 2026)
• NABOTA® / Jeuveau®: FDA-approved in the United States as prabotulinumtoxinA-xvfs (current as of mid 2026)

These are the primary FDA-approved Botox products from Korea currently recognized within the U.S. regulatory framework.

Non-FDA-Approved Korean Brands

The following products may hold approvals in South Korea and other international jurisdictions but are not currently FDA-approved in the United States:

• INNOTOX® (current as of June 2026)
• BOTULAX® (current as of June 2026)
• MEDITOXIN® (current as of June 2026)
• LIZTOX® (current as of June 2026)
• Re N Tox® (current as of June 2026)

Practitioners should verify regulatory status within their own jurisdiction before procurement and clinical use.

Botox Units Explained: 100 vs 200 Units, Reconstitution & Storage

Beyond formulation type and manufacturer, unit configuration is another important factor when comparing Korean botulinum toxin products. Available unit sizes, reconstitution requirements, and storage considerations all affect inventory management, treatment planning, and clinical workflow.

100 Units vs 200 Units

The 100-unit presentation is the standard format for most Korean brands and suits routine aesthetic injectable procedures. Products offering 200 units, including BOTULAX® and MEDITOXIN®, can be advantageous for high-volume clinics, practices treating multiple patients daily, or practitioners treating several treatment areas in a single session.

More importantly, botulinum toxin units are not interchangeable across manufacturers, and brand-specific dosing recommendations should always be followed.

Common Treatment Areas

• Forehead lines
• Crow’s feet
• Glabellar lines
• Lines between the eyebrows
• Masseter hypertrophy
• Perioral wrinkles and lines

These treatments work by reducing activity within targeted facial muscles, softening expression lines.

How Long Does Korean Botox Last?

Regarding the common question of how long Korean Botox lasts, effects typically last roughly 3–6 months, though duration varies by patient, injection technique, treatment area, and product. Individual outcomes vary, and maintenance schedules should be guided by clinical assessment.

Reconstitution and Storage

For lyophilized products, reconstitution involves adding sterile normal saline according to the manufacturer’s labeling. Products requiring reconstitution include LETYBO™, BOTULAX®, NABOTA®, MEDITOXIN®, LIZTOX®, and Re N Tox®. INNOTOX® is the primary exception, supplied as a ready-to-use liquid.

Most products require refrigerated storage at 2–8°C and protection from light. Reconstituted vials should be used within the stability period specified by the manufacturer.

Best Korean Botulinum Toxin: INNOTOX® vs NABOTA® & BOTULAX® vs MEDITOXIN®

There is no universally accepted “best” Korean botulinum toxin. Selection depends on practice priorities, regulatory considerations, workflow preferences, and treatment volume.

INNOTOX® vs NABOTA®

BOTULAX® vs MEDITOXIN®

For many clinics, the decision comes down to preferred manufacturer relationships, available unit sizes, and workflow considerations.

Korean Botox as an Alternative

Many practitioners view Korean neurotoxins as an alternative to established Western Botox products. The category has earned recognition as a high-quality, cost-effective alternative while continuing to expand globally, supported by manufacturing standards, formulation diversity, and a full product range that has driven the rise of Korean Botox in modern aesthetic medicine.

Where Can Practitioners Buy Korean Botox Online?

Korean Botox is intended for qualified professionals only. Practitioners looking to buy botulinum toxins or buy Korean Botox wholesale should work only through qualified channels intended for licensed aesthetic clinics, dermatology practices, and compounding pharmacists. When buying online, it is important to review product documentation carefully, including certificates of analysis, purity verification, GMP manufacturing information, and LOT number traceability. Clinics should also check for wholesale buying options that align with their treatment volume and inventory requirements.

Medical Spa Rx offers guidance and documentation support to help professionals evaluate sourcing information, and practitioners may contact the professional support team for additional assistance.

Frequently Asked Questions

1. How do the main Korean Botox brands differ from each other?

The primary differences involve formulation type, manufacturer, regulatory status, and available unit configurations. INNOTOX® is liquid, while most others are lyophilized. LETYBO™ and NABOTA® currently have FDA-recognized pathways in the U.S., while other products primarily hold approvals in South Korea and other international markets.

2. Which is better between INNOTOX® vs NABOTA®?

Neither is objectively better. INNOTOX® offers convenience through its liquid formulation, while NABOTA® provides FDA-recognized regulatory standing and extensive international clinical data.

3. What are the differences between BOTULAX® vs MEDITOXIN®?

BOTULAX® is produced by Hugel and offered in 100- and 200-unit presentations. MEDITOXIN® is produced by Medytox and available in 100-, 150-, and 200-unit configurations.

4. Which Korean Botox brands have FDA approval?

Based on the information currently available, LETYBO™ and NABOTA®/Jeuveau® have FDA approval (as of mid 2026). Practitioners looking to order Korean botox must provide a valid license.

5. What is INNOTOX®, and how does its liquid formulation affect clinical use?

INNOTOX® is a liquid botulinum toxin type A product manufactured by Medytox. Because it does not require reconstitution, preparation time may be reduced, and concentration remains standardized.

6. What does the reconstitution process involve for Korean Botox?

Reconstitution involves adding sterile normal saline to lyophilized neurotoxins according to the manufacturer’s instructions. INNOTOX® is the primary exception because it is supplied as a liquid formulation.

7. How should I evaluate Korean Botox suppliers, and what should I look for?

Evaluate GMP certification, regulatory status, clinical evidence, storage requirements, product documentation, LOT traceability, and certificates of analysis. Regulatory information should always be verified at the time of procurement.

Sources

1. Rho NK, Han KH, Kim HS. An update on the cosmetic use of botulinum toxin: the pattern of practice among Korean dermatologists. Toxins (Basel). 2022;14(5):329. doi:10.3390/toxins14050329
2. Beer KR, Shamban AT, Avelar RL, Gross JE, Jonker A. Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results from 2 identical phase III studies. Dermatol Surg. 2019;45(11):1381‑1393. doi:10.1097/DSS.0000000000001903
3. Molina B, Grangier Y, Mole B, et al. Patient satisfaction after the treatment of glabellar lines with botulinum toxin type A (Speywood unit): a multicentre European observational study. J Eur Acad Dermatol Venereol. 2014;29(7):1382‑1388. doi:10.1111/jdv.12881
4. Gold M, Taylor S, Mueller DS, et al. Efficacy and safety of letibotulinumtoxina in the treatment of moderate and severe glabellar lines in females 35 to 50 years of age: post hoc analyses of the phase 3 clinical study data. Aesthet Surg J Open Forum. 2024;6:ojae010. Published 2024 Feb 23. doi:10.1093/asjof/ojae010

The page and all of its displayed contents are for medical professionals, designed to inform only, and not as a replacement for medical advice.